本文選題：PTA　切入點：LTBELISA　出處：《基因組學(xué)與應(yīng)用生物學(xué)》2017年10期

【摘要】：本研究發(fā)現(xiàn)位于大腸桿菌不耐熱腸毒素B亞單位(heat-labile enterotxin B subunit,LTB)的8肽(octapetptide,PT8A)具有一定的佐劑活性。我們用PT8A聯(lián)合人手足口病病毒的VP1(EVP1)鼻腔免疫Balb/c小鼠,通過間接ELISA法檢測小鼠血清中的特異性EVP1抗體滴度,檢測結(jié)果顯示PT8A+EVP1組相比PBS組和EVP1組有明顯佐劑活性,初步驗證了PT8A的佐劑活性。對PT8A和LTB蛋白的佐劑活性進行比較研究,結(jié)果顯示,PT8A的佐劑活性明顯弱于LTB,有待進一步提高。通過對PT8A免疫原性進行檢測分析發(fā)現(xiàn),PT8A的免疫原性明顯減弱,初步確定PT8A在保留佐劑活性的同時自身免疫原性明顯減弱,具有進一步開發(fā)為粘膜免疫佐劑候選分子的潛力。
[Abstract]:In this study, it was found that octapetptide PT8A, an octapetptide PT8A, which is located in the subunit of heat-labile enterotxin B subunit LTB, has a certain adjuvant activity.Balb/c mice were immunized with PT8A combined with human HFMD virus (VP1EVP1) nasal cavity. The titer of specific EVP1 antibody in serum was detected by indirect ELISA method. The results showed that PT8A EVP1 group had significant adjuvant activity compared with PBS group and EVP1 group.The adjuvant activity of PT8A was preliminarily verified.The adjuvant activity of PT8A and LTB protein was compared. The results showed that the adjuvant activity of PT8A was obviously weaker than that of LTB, which needed to be further improved.Through the detection and analysis of PT8A immunogenicity, it was found that the immunogenicity of PT8A was obviously weakened. It was preliminarily confirmed that PT8A had the potential to be a candidate molecule for mucosal immune adjuvant while preserving its adjuvant activity.
【作者單位】： 重慶醫(yī)科大學(xué);分子醫(yī)學(xué)與腫瘤研究中心;
【基金】：病原微生物生物安全國家重點實驗室開放課題(SKLPBS1523)資助
【分類號】：R392

【相似文獻】

相關(guān)期刊論文 前3條

1 周紅莉;郭麗;王健偉;洪濤;;粘膜免疫佐劑研究進展[J];中國生物工程雜志;2006年03期

2 張國廣;羅茂春;董艷美;陳亮;;LTB的表達及其粘膜免疫佐劑活性分析[J];廈門大學(xué)學(xué)報(自然科學(xué)版);2012年05期

3 程芳,李淑琴,舒東,張兆山,曹勇;新型粘膜免疫佐劑候選株LTA~ˉB~+的構(gòu)建[J];軍事醫(yī)學(xué)科學(xué)院院刊;2000年03期

，

本文編號：1708766